Phase 1 study of tumor-infiltrating lymphocytes (TIL) in patients with glioblastoma

Trial Profile

Phase 1 study of tumor-infiltrating lymphocytes (TIL) in patients with glioblastoma

Planning
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Tumour infiltrating lymphocytes (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Iovance Biotherapeutics
  • Most Recent Events

    • 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
    • 04 Nov 2016 According to Lion Biotechnologies media release, this trial is expcted to initiate in 2017.
    • 05 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top